Prelude Therapeutics (PRLD) Stock Statistics & Valuation Metrics

Prelude Therapeutics has a market cap or net worth of $46.00M. The enterprise value is $830.31M.

Prelude Therapeutics has 43,610,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Prelude Therapeutics’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -91.57%.

The current PE Ratio of Prelude Therapeutics is -0.76. Prelude Therapeutics’s PEG ratio is -0.36.

In the last 12 months, Prelude Therapeutics had revenue of 7.00M and earned -127.17M in profits. Earnings per share was -1.68.

In the last 12 months, operating cash flow was -105.33M and capital expenditures -522.00K, giving a free cash flow of -105.85M billion.

Prelude Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Prelude Therapeutics upcoming earnings date is Aug 13, 2025, Before Open (Confirmed).

Prelude Therapeutics as a current ratio of 5.30, with Debt / Equity ratio of -0.52%

In the past 12 months, Prelude Therapeutics has paid 0.00 in taxes.

Prelude Therapeutics EV to EBITDA ratio is -0.73, with an EV/FCF ratio of -0.98.

Prelude Therapeutics has $99.07M in cash and marketable securities with $17.92M in debt, giving a net cash position of -$81.15M billion.

Gross margin is 0.00%, with operating margin of -1995.91%, and net profit margin of -1816.76%.

The average price target for Prelude Therapeutics is $3.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy